CKD-Associated Anemia: Pathophysiology, Diagnosis, and Treatment

1. Erythropoietin (EPO) Deficiency (Primary)

• Kidneys produce ~90% of EPO (peritubular fibroblasts in renal cortex)
• GFR <45 → ↓ EPO production → reduced RBC precursor stimulation
• Loss correlates with degree of renal fibrosis, not just GFR
• Board point: EPO levels are relatively low-normal or low in CKD anemia (inappropriate for degree of anemia)

2. Iron Deficiency (Common Complicating Factor)

• Absolute iron deficiency: Depleted body iron stores (TSAT <20%, ferritin <100 ng/mL)
  • Causes: GI blood loss, dialysis membrane loss, phlebotomy for labs
  • Enteral iron absorption impaired in CKD (uremia, phosphate binders)
• Functional iron deficiency: Adequate body iron but EPO resistance due to impaired iron mobilization
  • ESA therapy without concurrent iron repletion → worsening iron stores

3. Reduced RBC Lifespan (Moderate)

• Normal RBC lifespan: 120 days
• CKD RBC lifespan: 60-90 days (shortened by ~30-50%)
• Mechanisms: Uremic toxins, oxidative stress, altered RBC membrane
• Clinical significance: Even with normal EPO, RBC production cannot match increased turnover

4. Additional Contributing Factors

• Chronic inflammation: CRP, IL-6, TNF-α → hepcidin ↑ (blocks iron absorption)
• Nutritional deficiencies: B12, folate, copper
• Medications: ACE-I/ARB ↓ EPO; PPI ↓ iron absorption
• Comorbidities: Bleeding (GI ulcers, varices in liver disease), hemolysis

When to Screen for Anemia in CKD

• GFR <60 mL/min/1.73m² → annual screening
• GFR 30-59 → at least annual
• GFR <30 → every 3-6 months (higher risk)

Iron Status Assessment (Critical Before ESA Therapy)

Additional Labs

• CBC: Hemoglobin, MCV (microcytic if iron deficiency)
• Reticulocyte count: Should be elevated if EPO working; low reticulocyte count suggests inadequate EPO response or iron deficiency
• EPO level: Rarely needed; not used for dosing (many “normal” labs are inappropriately LOW for degree of anemia)
• B12, folate, copper: Screen if macrocytic anemia or neuropathy present
• Peripheral smear: Rule out hemolysis, schistocytes (HUS/TTP)

Oral Iron

• Route selection: In nondialysis CKD/PD, choose oral or IV iron by anemia severity, iron deficit, tolerability, response, access, and preference; eGFR 45 is not a route threshold.
• Formulations: Ferrous sulfate (FeSO₄) 325 mg daily = 65 mg elemental iron; ferrous gluconate (less GI upset)
• Select elemental iron dose and schedule by formulation, tolerance and response; the tablet mass is not the elemental iron dose.
• Timing: On empty stomach for better absorption; separate from calcium binders (↓ absorption by 40%)
• Side effects: GI upset (~30%), constipation, black stools, adherence issues
• Expected response: ↑ Hb by 0.5-1 g/dL per month
• Pitfall: Enteric-coated formulations bypass absorption site; avoid

Intravenous Iron (Preferred in Dialysis; Consider if Oral Fails)

Advantages: Bypasses GI barrier, doesn’t require gastric acid, rapid iron repletion

IV iron formulations differ: Use the specific product label for dose, dilution, interval, and monitoring. All products can cause hypersensitivity; ferric carboxymaltose also warrants attention to hypophosphatemia. Do not transfer one product’s schedule to another or claim zero anaphylaxis risk.

Iron replacement: Use the selected product label and a population-appropriate repletion plan, with baseline Hb, ferritin and TSAT. An iron-deficit calculation using Hb 15 g/dL is not an ESA hemoglobin target. During iron treatment, check Hb/ferritin/TSAT about every 3 months in nondialysis CKD/PD and every 1–3 months in HD; assess sooner after blood loss, treatment changes or an unexpected response.

Adverse effects: Transient hypophosphatemia (FCM), arthralgias/myalgias (transient), rare anaphylaxis (mostly iron dextran; <1% with modern formulations)

Pathophysiology of ESA Action

• Recombinant EPO (epoetin alfa/beta) or long-acting darbepoetin alfa
• Binds EPO receptor on erythroid progenitors → ↑ proliferation, maturation
• Requires adequate iron, B12, folate

Indications for ESA Initiation

• ESA initiation: Correct reversible causes first. In dialysis, consider initiation around Hb ≤9–10 g/dL. Without dialysis, individualize the decision—often in the 8.5–10 range—using symptoms, transfusion avoidance, and cardiovascular/thrombotic or malignancy risks.
• Hb alone does not mandate ESA or transfusion; active bleeding, ischemic symptoms, instability, expected benefit, and treatment risks change the decision.
• Correct iron deficiency and other reversible causes, then reassess Hb trajectory and symptoms. Do not impose a universal 4–6-week delay before an individualized ESA decision.

ESA Agents & Dosing

Dosing principles: Use the product-specific initial regimen and the lowest effective dose, with reassessment of hemoglobin trajectory, iron status, and reversible causes of poor response. Avoid automatic escalation or rapid hemoglobin rise. Individualize the target below 11.5 g/dL during adult ESA treatment.

Target Hemoglobin & Cardiovascular Safety

• TREAT Trial (2009): Darbepoetin to Hb approximately 13 g/dL vs placebo (rescue darbepoetin only if Hb <9) in T2DM + non-dialysis CKD → NO reduction in death/CV events or death/ESRD; stroke nearly doubled (HR 1.92, 95% CI 1.38–2.68) [1]
• CHOIR Trial (2006): Epoetin alfa to Hb 13.5 vs 11.3 g/dL → ↑ composite of death, MI, HF hospitalization, and stroke (HR 1.34, 95% CI 1.03–1.74) [2]
• ESA treatment: KDIGO 2026 recommends an adult hemoglobin target below 11.5 g/dL during ESA treatment. Initiation and maintenance should be individualized using symptoms, transfusion risk, dialysis status, iron status, and cardiovascular or thrombotic risk. Avoid normalizing hemoglobin with ESAs.

Mechanism

• Blocks degradation of HIF (hypoxia-inducible factor) → ↑ endogenous EPO production
• HIF stabilization can reduce hepcidin and improve iron availability; its effects and clinical safety are agent- and population-dependent.
• Oral agents: roxadustat, daprodustat, vadadustat

Agents & Evidence

• Roxadustat: Oral, dosed 3× weekly. Approved outside the US (including China and Japan); not FDA-approved in the United States
• Daprodustat: FDA approval in 2023 covered adults receiving dialysis for at least 4 months. US Jesduvroq was subsequently discontinued commercially; FDA determined withdrawal from sale was not for safety or effectiveness. Approval history does not establish current local availability.
• Vadadustat: The US label covers adults with CKD anemia receiving dialysis for at least 3 months. Review contraindications, cardiovascular/thrombotic risks and the product-specific monitoring plan; it is not indicated for nondialysis CKD anemia.
  • INNO2VATE (dialysis-dependent CKD): non-inferior to darbepoetin alfa for MACE (HR 0.96, 95% CI 0.83–1.11) and for Hb correction/maintenance [3]
  • PRO2TECT (non–dialysis-dependent CKD): met the Hb non-inferiority margin but did NOT meet the cardiovascular non-inferiority margin (MACE HR 1.17, 95% CI 1.01–1.36) [4]
• Class advantage: oral dosing; ↓ hepcidin may improve iron availability
• Class caution: cardiovascular safety is not uniform across agents or across dialysis status — do not assume a class effect

When to Use HIF-PHI vs ESA

• HIF-PHI selection: KDIGO 2026 generally favors an ESA as first-line erythropoietic therapy after correcting reversible causes. A HIF-PHI decision requires approved local eligibility, treatment risks, and shared choice; injection refusal or ESA hyporesponsiveness alone does not establish eligibility.
• Neither an ESA nor a HIF-PHI provides immediate correction of unstable acute anemia; use an urgent cause-directed and transfusion assessment when appropriate.
• Monitoring: Follow hemoglobin trend, blood pressure, iron status, and product-specific safety guidance. Individualize treatment rather than pursuing a normal hemoglobin.

Step 1: Confirm Iron Sufficiency

• Use the dialysis-status-specific ferritin AND TSAT initiation criteria described above. Choose route by clinical need and response; low TSAT alone is not an automatic iron order.
• Reassess iron response and other correctable causes before ESA escalation; use Hb trajectory, symptoms and the product label rather than a mandatory waiting interval.
• Recheck ferritin and TSAT before starting ESA

Step 2: Initiate ESA or HIF-PHI

• ESA: Use an individualized indication and the actual product’s initial dosing guidance; do not extrapolate an IV hemodialysis schedule to every nondialysis patient.
• HIF-PHI: Confirm the product’s approved population and discuss harms/benefits; this is not an automatic substitute whenever an ESA is contraindicated.
• Individualize the hemoglobin target; in adults treated with an ESA, keep the target below 11.5 g/dL.

Step 3: Titrate Dose

• Reassess Hb about every 2–4 weeks after starting or changing ESA therapy; use the product-specific adjustment rules, Hb trajectory, and lowest effective dose rather than a universal increment.
• During iron treatment, monitor Hb, ferritin and TSAT every 3 months in nondialysis CKD/PD and every 1–3 months in HD; shorten the interval when clinical changes require it. Reticulocytes are part of assessment when indicated, not a universal monthly order.
• Avoid maintaining adult Hb at or above 11.5 g/dL with an ESA. Reduce or hold dosing according to the specific product label, Hb trajectory and rapid-rise rules; do not apply one fixed 25% decrement to every product or situation.

Step 4: Monitor for Hyporesponsiveness

• If response is inadequate or dose requirements rise despite adequate iron, investigate reversible causes and reassess the treatment plan; a single epoetin-equivalent cutoff does not define all ESA hyporesponsiveness.
• Consider: Blood loss, inflammation (CRP), hemolysis (haptoglobin, LDH), malignancy, infection, copper deficiency

Step 5: Transition to Dialysis or Transplant

• Dialysis follow-up: Reassess the need for iron and ESA using Hb trajectory, ferritin/TSAT, symptoms, treatment risks and ongoing losses; neither treatment continues automatically.
• After transplant: Reassess anemia, graft function, bleeding, iron status, infection, and medication effects. Do not automatically stop or taper solely because transplantation occurred.